Imlunestrant trials for Breast cancer

All Imlunestrant trials · All Breast cancer trials

Phase breakdown

Recruiting trials studying Imlunestrant for Breast cancer

• A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
  NCT07287098 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 89 locations
• A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
  NCT05307705 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 50 locations
• First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
  NCT05768139 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 65 locations
• Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial
  NCT07191717 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

How many trials study Imlunestrant for Breast cancer?

4 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.